Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 423.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,835 shares of the biopharmaceutical company’s stock after purchasing an additional 16,854 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,316,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. raised its stake in Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares in the last quarter. FNY Partners Fund LP raised its stake in Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares in the last quarter. Alpha Windward LLC raised its stake in Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares in the last quarter. Finally, IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals by 33.2% during the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 96 shares in the last quarter. 67.80% of the stock is owned by institutional investors and hedge funds.

In related news, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. Insiders have sold 61,460 shares of company stock worth $29,143,390 in the last three months. Insiders own 10.80% of the company’s stock.

WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Stake Raised by Los Angeles Capital Management & Equity Research Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-stake-raised-by-los-angeles-capital-management-equity-research-inc/1713949.html.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $391.59 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The stock has a market cap of $41,959.26, a PE ratio of 33.90, a price-to-earnings-growth ratio of 1.54 and a beta of 1.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the prior year, the firm earned $3.13 earnings per share. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

A number of research firms have commented on REGN. Morgan Stanley restated an “equal weight” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 23rd. Canaccord Genuity restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Barclays PLC lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $450.00 to $395.00 in a research note on Friday, October 20th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 27th. Finally, Leerink Swann restated an “outperform” rating and issued a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average target price of $475.34.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.